Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 108 from EUR 121 and keeps a Buy rating on the shares after the company and partner Regeneron (REGN) announced mixed results from itepekimab’s Phase 3 COPD trials. The firm’s price target change is driven by the removal of itepekimab and SAR441566 forecasts, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
- Sanofi exercises license extension option to Nurix’s STAT6 program
- Sanofi to Acquire Blueprint Medicines for $9.5 Billion, Expanding Rare Disease Portfolio
- Sanofi resumed with an Equal Weight at Morgan Stanley